Omeros (OMER) Shares Outstanding (Diluted Average) (2019 - 2026)
Omeros recorded quarterly Shares Outstanding (Diluted Average) of $90.1 million in Q1 2026, up 55.22% quarter-over-quarter from $58.1 million in Q1 2025, and up 55.22% year-over-year from $58.1 million in Q1 2025.
Omeros' Shares Outstanding (Diluted Average) history runs 7 years deep, the most recent figure standing at $90.1 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 55.22% year-over-year to $90.1 million; the TTM figure through Mar 2026 stood at $90.1 million (up 55.22% YoY), while the FY2022 annual figure was $62.7 million, up 0.63% from the prior year.
- Shares Outstanding (Diluted Average) came in at $90.1 million for Q1 2026 at Omeros, up from $58.1 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $90.1 million in Q1 2026 to a low of $58.1 million in Q1 2025.
- A 4-year average of $65.6 million and a median of $62.7 million in 2022 frame the typical range for Shares Outstanding (Diluted Average).
- Across the five-year window, Shares Outstanding (Diluted Average) grew 0.17% in 2023 and surged 55.22% in 2026, its largest moves.
- Omeros' Shares Outstanding (Diluted Average) stood at $62.7 million in 2022, then climbed by 0.16% to $62.8 million in 2023, then dropped by 7.61% to $58.1 million in 2025, then soared by 55.22% to $90.1 million in 2026.
- According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods registered $90.1 million, $58.1 million, and $62.8 million for Q1 2026, Q1 2025, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | 90.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 90.12 Mn |
| Mar 31, 2025 | 58.06 Mn |
| Jun 30, 2023 | 62.84 Mn |
| Mar 31, 2023 | 62.83 Mn |
| Dec 31, 2022 | 62.74 Mn |
| Sep 30, 2022 | 62.73 Mn |
| Jun 30, 2022 | 62.73 Mn |
| Mar 31, 2022 | 62.72 Mn |
| Dec 31, 2021 | 62.34 Mn |
| Sep 30, 2021 | 62.51 Mn |
| Jun 30, 2021 | 62.37 Mn |
| Mar 31, 2021 | 61.93 Mn |
| Dec 31, 2020 | 57.18 Mn |
| Sep 30, 2020 | 55.68 Mn |
| Jun 30, 2020 | 54.41 Mn |
| Dec 31, 2019 | 49.52 Mn |